Latest Licensing News

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

Paladin Energy has achieved a significant regulatory milestone with formal environmental approval for its Patterson Lake South uranium project in Saskatchewan, Canada, paving the way for construction licensing.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

LaserBond Ltd has reported a robust first half of FY26, with revenue up 13.4% and net profit after tax more than doubling, underpinned by a significant licensing agreement with Komatsu and ongoing R&D investments.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

McLaren Minerals has kicked off a major drilling campaign at its McLaren Titanium Project aiming to upgrade resource classifications and expand its substantial 529 million tonne resource base. The program is a critical step toward advancing the project’s development and future feasibility studies.

PLS Group has acquired Calix’s stake in their joint lithium processing venture, gaining full ownership and operational control while securing a royalty-free licence for Calix’s calciner technology.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Kinatico Ltd reports robust H1 FY26 results, driven by a 49.5% surge in SaaS revenue and the launch of its AI-powered Kinatico Compliance platform, significantly broadening its addressable market.

Botanix Pharmaceuticals has secured approximately A$45 million through a two-tranche placement and an underwritten security purchase plan to fund API purchases, derisk its supply chain, and accelerate growth of its flagship product Sofdra.